These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 7906781)

  • 1. Activated protein C resistance in deep-vein thrombosis.
    Legnani C; Palareti G; Biagi R; Coccheri S
    Lancet; 1994 Feb; 343(8896):541-2. PubMed ID: 7906781
    [No Abstract]   [Full Text] [Related]  

  • 2. Activated protein C resistance in venous thrombosis.
    Koster T; Rosendaal FR
    Lancet; 1994 Feb; 343(8896):541. PubMed ID: 7906780
    [No Abstract]   [Full Text] [Related]  

  • 3. Successful treatment of deep vein thrombosis in homozygous protein C deficiency with activated protein C.
    Wada H; Deguch K; Shirakawa S; Suzuki K
    Am J Hematol; 1993 Nov; 44(3):218-9. PubMed ID: 8213784
    [No Abstract]   [Full Text] [Related]  

  • 4. Evaluation of activated protein C resistance in stored plasma.
    Girolami A; Simioni P; Scarano L
    Lancet; 1994 May; 343(8908):1288-90. PubMed ID: 7910292
    [No Abstract]   [Full Text] [Related]  

  • 5. Resistance to activated protein C as an underlying cause of recurrent venous thrombosis during relapsing nephrotic syndrome.
    Petäjä J; Jalanko H; Holmberg C; Kinnunen S; Syrjälä M
    J Pediatr; 1995 Jul; 127(1):103-5. PubMed ID: 7608792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The incidence of activated protein C resistance among patients with deep vein thrombosis and healthy subjects in Osaka.
    Kambayashi J; Fujimura H; Kawasaki T; Sakon M; Monden M; Suehisa E; Amino N
    Thromb Res; 1995 Jul; 79(2):227-9. PubMed ID: 7676410
    [No Abstract]   [Full Text] [Related]  

  • 7. Acquired activated protein C-resistance in patients with lupus anticoagulants.
    Ehrenforth S; Radtke KP; Scharrer I
    Thromb Haemost; 1995 Aug; 74(2):797-8. PubMed ID: 8585027
    [No Abstract]   [Full Text] [Related]  

  • 8. [Apropos of the resistance to activated protein-C in venous thromboembolic accidents].
    Alhenc-Gelas M; Emmerich J; Aiach M; Fiessinger JN
    Presse Med; 1995 Apr; 24(16):784. PubMed ID: 7784421
    [No Abstract]   [Full Text] [Related]  

  • 9. High total and free protein S in patients with acute deep vein thrombosis.
    Toulon P; Gandrille S; Vitoux JF; Fiessinger JN; Sultan Y; Aiach M
    Thromb Res; 1990 Jul; 59(1):213-7. PubMed ID: 2144670
    [No Abstract]   [Full Text] [Related]  

  • 10. Apparent heparin resistance form elevated factor VIII in a patient with postoperative deep venous thrombosis. A case report.
    Cirisano FD; Lee S; Greenspoon JS
    J Reprod Med; 1996 Mar; 41(3):191-4. PubMed ID: 8778420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance to activated protein C as a basis for venous thrombosis.
    Svensson PJ; Dahlbäck B
    N Engl J Med; 1994 Feb; 330(8):517-22. PubMed ID: 8302317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein C concentrate in the treatment of warfarin-induced skin necrosis in the protein C deficiency.
    Lewandowski K; Zawilska K
    Thromb Haemost; 1994 Mar; 71(3):395. PubMed ID: 8029804
    [No Abstract]   [Full Text] [Related]  

  • 13. Improving use of heparin in acute deep venous thrombosis.
    Gold JA; Ferguson CJ; Williams NF; Braun SK
    Wis Med J; 1996 May; 95(5):311-2. PubMed ID: 8936037
    [No Abstract]   [Full Text] [Related]  

  • 14. Diagnosis of activated protein C resistance (factor V Leiden).
    Baker R; Thom J; van Bockxmeer F
    Lancet; 1994 Oct; 344(8930):1162. PubMed ID: 7934522
    [No Abstract]   [Full Text] [Related]  

  • 15. Management of iliofemoral thrombosis in a pregnant patient with heparin resistance.
    Anand SS; Brimble S; Ginsberg JS
    Arch Intern Med; 1997 Apr; 157(7):815-6. PubMed ID: 9125015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Therapy of deep venous thrombosis].
    Mesters RM
    Internist (Berl); 1999 Oct; 40(10):1098-9. PubMed ID: 10610366
    [No Abstract]   [Full Text] [Related]  

  • 17. [APC resistance: pathogenesis, diagnosis, prevalence and importance of a new thrombosis risk factor].
    Wankmüller H; Schwender S; Keller F
    Med Klin (Munich); 1996 May; 91(5):308-12, 324. PubMed ID: 8709909
    [No Abstract]   [Full Text] [Related]  

  • 18. Cost effectiveness and ease of administration of low molecular weight heparin in deep vein thrombosis.
    Teo CP; Lim HL; Kueh YK
    Thromb Haemost; 1994 Aug; 72(2):328-9. PubMed ID: 7831676
    [No Abstract]   [Full Text] [Related]  

  • 19. Activated protein C resistance--a major risk factor for thrombosis.
    Rosén SB; Sturk A
    Eur J Clin Chem Clin Biochem; 1997 Jul; 35(7):501-16. PubMed ID: 9263726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative dosage and toxicity of heparin sodium in the treatment of patients with pulmonary embolism versus deep-vein thrombosis.
    Tenero DM; Bell HE; Deitz PA; Bertino JS
    Clin Pharm; 1989 Jan; 8(1):40-3. PubMed ID: 2912663
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.